Buried in a technical document released by the Centers for Medicare and Medicaid Services is a convoluted paragraph that may ...

Halozyme Therapeutics shares tumbled Tuesday on a new Medicare approach to price negotiations for drugs that use additive ...

Despite Halozyme reporting generally positive first-quarter results, the stock was negatively impacted by the potential risk that its hyaluronidase combination products may face earlier price ...

Johnson & Johnson (NYSE:JNJ) stock and Halozyme (HALO) stock were downgraded at Leerink Partners on earlier than expected price controls for products. Read more here.

Halozyme Therapeutics posts strong Q1 2025 earnings with 35% revenue growth, robust pipeline, and rising royalties.

PhoreMost Ltd., a next-generation targeted protein degradation (TPD) company progressing a pipeline of degrader therapeutics within oncology and inflammation, today announced Barbara Duncan has joined ...

Learn more about whether BioCryst Pharmaceuticals, Inc. or Halozyme Therapeutics, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

We recently published a list of 10 Best Cancer Stocks to Invest in for Long-Term Gains. In this article, we are going to take ...

Halozyme Therapeutics HALO has outperformed the market over the past 15 years by 4.64% on an annualized basis producing an ...

Here is our list of the 10 best cancer stocks to invest in for long term gains. Summit Therapeutics Inc. (NASDAQ:SMMT) is a ...

We recently published a list of Why These 10 Stocks Soared Today. In this article, we are going to take a look at where ...

Although the revenue and EPS for Halozyme Therapeutics (HALO) give a sense of how its business performed in the quarter ended March 2025, it might be worth considering how some key metrics compare ...